Comparative study of intralosional steroid injection and cryotherapy in alopecia areata

Mehdi Amirnia, Seyed-Sajjad Mahmoudi, Farid Karkon-Shayan, Hossein Alikhah, Reza Piri, Mohammad Naghahi-Bezhad, Mohammad-Reza Ranjkesh

Department of Dermatology, Sina Hospital, Cardiovascular Disease Research Center, Students’ Research Committee, Medical Faculty, Medical Education Research Center, Medical Philosophy and History Research Center, Tabriz University of Medical Sciences, Tabriz, Iran

ABSTRACT

Background: Alopecia areata (AA) is a common, non-scarring type of hair loss, affecting approximately 2.1% of the population, many modality of treatment recommended like steroid injection, topical Immunotherapy and several systemic therapies. The aim of this study was to compare intralosional steroid injection and cryotherapy outcomes in AA. Materials and Methods: In an analytical-descriptive study, 120 AA patients treated with intralosional steroid injection and 120 AA patients treated with cryotherapy were randomly selected. These two groups matched for location, duration and size of lesion and also matched for age and gender. From March 2011 to September 2013, the effect and complications of the therapies after 3, 6, 9 and 12 weeks were assessed and results were compared between the two groups. Results: Mean age of patients in steroid injection group was 30.2 ± 6.8 and in cryotherapy group was 31.8 ± 7.1. Sexual distribution in both groups was 56.7% and 43.3 % for male and female, respectively. Location of disease in 80% was in scalp and 20% was in face in both groups. The time of beginning response in steroid group was 4.13 ± 2.13 weeks and in cryotherapy group was 6.14 ± 0.29 weeks, difference between two groups was significant (P = 0.001). In term of clinical response at the end of study, in steroid group, 20 patients (16.7%) no response, 32 patients (26.7%), moderate response and 68 patients (56.7%) had a complete response, and also in cryotherapy group was, 52 patients (43.3%) no response, 40 patients (33.3%) moderate response and 28 patients (23.3%) had a complete response. There was significant different in complete response rate and steroid injection was more effective than cryotherapy (P < 0.05). Conclusion: As the cryotherapy is a considerable treatment of AA, also this study proposes intralosional injection of corticosteroid, as a replacement of AA therapy; particularly the short-term complications are not significantly different.

Key words: Alopecia areata, cryotherapy, intralosional steroid injection

INTRODUCTION

Alopecia areata (AA) is an autoimmune disorder cause of inflammation-induced non-scarring type of hair loss, which consists of 1% patients referred to the dermatology clinic. AA due to the complications affects the patients’ quality of life and reduces their self-esteem. The lifetime risk of AA is about 2.1% and affects both children and adults with any kind of hair colour and there is no significant difference in terms of gender.

The precise aetiology of AA is still obscure. Current evidence suggests that AA is a T-cell mediated autoimmune disease directed against a putative autoantigen of the hair follicle. AA is generally associated with an increased risk of other autoimmune diseases like autoimmune thyroid disease. Histologically, lesional biopsies of AA demonstrate a peri-follicular and intra-follicular mononuclear cell infiltrate around anagen phase hair follicles. The infiltrate consists mostly of activated lymphocytes, in particular CD4+ T cells as well as dendritic cells and macrophage.

There is many kind of treatment modality in localised kind of AA. Injectable forms of corticosteroids are first line of AA therapy, and also topical use of steroids is widely used. Others are topical sensitisation with Anthralin, minoxidil and cryotherapy. In extensive form of AA, systemic treatments like corticosteroids, cyclosporine and methotrexate can be used.
The tissue response to cryotherapy ranges from an inflammatory reaction to mild or severe destruction. The response to cryo can be divided to two mechanisms: Early effect and delayed effect. The early effect is due to formation of ice crystal which can distract cells due to direct effect or osmotic effect. The delayed effect included vascular damage, apoptosis and immunological effect, vascular constriction, platelet aggravation, ischaemia, increased permeability. So because of those effects it can be effective in AA. None of the available treatments of AA have not been approved by Food and Drug Administration (FDA) and do not have a protective role.

Aim of this study was to compare two treatment modalities of AA including intralesional steroid injection and cryotherapy.

**MATERIALS AND METHODS**

In a descriptive-analytical study from March 2011 to September 2013, we randomly selected using Rand list (version 1.2) software and investigated 120 AA patients treated with intralesional steroid injection and 120 AA patients treated with cryotherapy who had referred to dermatology clinic of Sina Educational Centre of Tabriz (which is a referral center for dermatology in the North West of Iran).

These two groups matched for location, duration and size of lesion and also matched for age and gender. The manner of cryotherapy was superficial cryotherapy using liquid nitrogen spray two cycles each one 3-5 second and steroid manner was injecting 5 mg/ml triamcinolone acetonide per session. Patients in both groups were treated with mentioned methods, for four sessions with an interval of 3 weeks. Response and complications were inspected among clinical treatment in 3, 6, 9 and 12 weeks. Clinical response was defined as hair regrowth in the manner of without response (0-30% regrowth), mild response (30-60% regrowth), moderate (60-90% regrowth) and complete response (90-100% regrowth).

Collected information has been presented as mean ± standard deviation (mean ± SD) and also as frequency and percentage. Implemented software program was SPSS™ version 16. To compare quantitative variables Student T-test was used and for qualitative variables Chi-square and Fischer exact test if needed, have been used. In all cases of study, results were statistically considered as significant with \( P \leq 0.05 \).

**RESULTS**

Mean age of patients in steroid injection group was 30.2 ± 6.8 and in cryotherapy group was 31.8 ± 7.1. In both groups 68 (56.7%) Of patients were male and 52 (43.3%) were female. Age range of patients in cryotherapy group was 14-40 years and in steroid injection were 17-38 years. Duration of disease in 83.3% of patient is shorter the 6 month and in 16.7% of patient longer than 6 month in both groups. Location of disease in 80% was in scalp and 20% was in face in both groups.

The time of beginning response in steroid group was 4.13 ± 2.13 weeks and in cryotherapy group was 6.14 ± 0.29 weeks, difference between two groups was significant (\( P = 0.001 \)).

Clinical response 3 weeks after each session of therapy in both groups was according to Table 1.

There was significant different in complete response rate between two groups and steroid injection was more effective than cryotherapy (\( P < 0.05 \)). Local corticosteroid injection efficiency was 83.3% and cryotherapy 56.7%. Local corticosteroid injection was significantly more effective than cryotherapy (\( P = 0.05 \)).

Complications in steroid injection group were in 13.3% patients (75% pain and 25% atrophy) and in

| Evaluation time | Group                        | Without response (%) | Mild response (%) | Moderate response (%) | Complete response (%) |
|-----------------|------------------------------|----------------------|-------------------|-----------------------|----------------------|
| 3 weeks after the first session of therapy (week 3th) | Steroid injection group     | 52 patients (43.3)   | 68 patients (56.7) | —                     | —                    |
|                 | Cryotherapy group            | 120 patients (100)   | —                 | —                     | —                    |
| 3 weeks after the second session of therapy (week 6th) | Steroid injection group     | 28 patients (23.3)   | —                 | —                     | —                    |
|                 | Cryotherapy group            | 120 patients (100)   | —                 | —                     | —                    |
| 3 weeks after third session of therapy (week 9th) | Steroid injection group     | 52 patients (43.3)   | 64 patients (53.3) | 4 patients (3.3)      | 16 patients (13.3)   |
|                 | Cryotherapy group            | 28 patients (23.3)   | —                 | 76 patients (63.3)    | —                    |
| Clinical response at the end of study (week 12th) | Steroid injection group     | 52 patients (43.3)   | 16 patients (13.3) | 52 patients (43.3)    | 68 patients (56.7)   |
|                 | Cryotherapy group            | 20 patients (16.7)   | —                 | 32 patients (26.7)    | —                    |
cryotherapy group were in 6.7% patients (50% bullae and 50% erythema), difference was not significant ($P = 0.671$).

**DISCUSSION**

The main aetiology for the occurrence of AA is not clear; the evidence is in favour of an autoimmune disease. Disease changes with genetic factors, and is exacerbated by stress. Conventional treatments of AA include intralesional, phototherapy and systemic steroid therapy. Cryotherapy can also be useful in the treatment of AA.

In this study, the treatment of local injection of low dose corticosteroid (5 mg per ml) use in AA patients compared with cryotherapy. The response to treatment was determined based on the regrowth of hair in the 3, 6, 9 and 12 weeks after treatment. The response at the local corticosteroid injection group was significantly better than the group treated with cryotherapy ($P < 0.05$). The average time for onset of hair growth after treatment with topical corticosteroid injection group was significantly shorter than in the group treated with cryotherapy ($P = 0.001$). The efficiency of topical corticosteroid injection in AA treatment, based on the average or total hair regrowth, was 80% and significantly better comparing with cryotherapy 56.7% ($P = 0.05$).

A descriptive study of 10 patients concluded that intralesional corticosteroid injection is a safe and effective treatment of extensive AA, and several review studies suggest the intralesional steroid injection as an effective and almost safe treatment of AA.

In a retrospective study of 153 patients with AA treated by cryotherapy, positive therapeutic responses were in 68.6% of patients. This study suggests that cryotherapy can be the first line of treatment in mild form of AA especially in children due to less of pain and side effects. In recent study efficiency cryotherapy was 56.7% and also complications of cryotherapy just were in 6.7% patients. Also, a study reported the use of superficial cryotherapy to increase eyebrow hair growth due to AA.

In a cohort of 290 patients of AA, after 1-2 intralesional steroid injections using 61% of patients were cured. In our analytical-descriptive study, local corticosteroid injection efficiency was 83.3% and complications of that were only in 13.3% patients (75% pain and 25% atrophy) and significant complications were not observed.

Considering different complications of therapies designated for AA treatment reported in various studies. We recommend do this study in more cases to evaluate perfect effect and complication of these two methods and perform a randomised clinical trial about this topic.

**CONCLUSIONS**

As the cryotherapy is a considerable treatment of AA, also this study proposes intralesional injection of corticosteroid, as a replacement of AA therapy; particularly the short-term complications are not significantly different.

**REFERENCES**

1. Kar BR, Handa S, Kumar B. Placebo-controlled oral pulse prednisolone therapy in alopecia areata. J Am Acad Dermatol 2005;52:287-90.
2. Paus R, Arck P. Neuroendocrine perspectives in alopecia areata: Does stress play a role? J Invest Dermatol 2009;129:1324-6.
3. Mirzoyev SA, Schrum AG, Davis MD, Torgerson RR. Lifetime incidence risk of alopecia areata estimated at 2.1% by Rochester Epidemiology Project, 1990-2009. J Invest Dermatol 2014;134:1141-2.
4. Gilhar A, Paus R, Kalish RS. Lymphocytes, neuropeptides, and genes involved in alopecia areata. J Clin Invest 2007;117:2019-27.
5. Ishak RS, Piliang MP. Association between alopecia areata, psoriasis vulgaris, thyroid disease, and metabolic syndrome. J Investig Dermatol Symp Proc 2013;16:S56-7. Nature Publishing Group; 2013.
6. Huang KP, Mullangi S, Guo Y, Qureshi AA. Autoimmune, atopic, and mental health comorbid conditions associated with alopecia areata in the United States. JAMA Dermatol 2013;149:789-94.
7. McElwee KJ, Freyenschmidt-Paul P, Hoffmann R, Kissling S, Hummel S, Vitacolonna M, et al. Transfer of CD8(+) cells induces localized hair loss whereas CD4(+)/CD25(-) cells promote systemic alopecia areata and CD4(+)/CD25(+) cells blockade disease onset in the C3H/HeJ mouse model. J Investig Dermatol 2005;124:947-57.
8. Miteva M, Tosti A. Treatment options for alopecia areata. J Drugs Dermatol 2009;8:909-12.
9. Shapiro J. Current treatment of alopecia areata. Jnvestig Dermatol Symp Proc 2013;16:S42-4. Nature Publishing Group; 2013.
10. James WD, Berger T, Elston D. Andrew’s diseases of the skin: Clinical dermatology. Elsevier Health Sciences; 2011, volume 10, 403-15
11. Shapiro J. Dermatologic therapy: Alopecia areata update. Dermatol Ther 2011;24:301.
12. Park KY, Jang WS, Son IP, Choi SY, Lee MY, Kim BJ, et al. Combination therapy with cyclosporine and psoralen plus ultraviolet a in the patients with severe alopecia areata: A retrospective study with a self-controlled design. Ann Dermatol 2013;25:12-6.
13. Hong SP, Jeon SY, Oh TH, Lee WS. A retrospective study of the effect of superficial cryotherapy on alopecia areata. Korean Journal of Dermatology. 2006;44:274-80.
14. Chang KH, Rojhirunsakool S, Goldberg LJ. Treatment of severe alopecia areata with intralesional steroid injections. J Drugs Dermatol 2009;8:909-12.
15. Alkilafiah A. Topical and intralesional therapies for alopecia areata. Dermatol Ther 2011;24:355-63.
16. Ito T. Advances in the management of alopecia areata. J Dermatol 2012;39:11-7.
17. Subramaniam, Keerthi, Saritha M, Karthikeyan K. Hair: Therapy and Transplantation; 2014;4:1-3.
18. Messenger AG, McKillop J, Farrant P, McDonagh AJ, Sladden M. British Association of Dermatologists’ guidelines for the management of alopecia areata 2012. Br J Dermatol 2012;166:916-26.
19. Jeon SY, Ahn BK, Lee S, Lee WS. Superficial Cryotherapy of Alopecia Areata in Eyebrows. Korean Journal of Dermatology 2004;42:1024-7.
20. Ranawaka RR. An observational study of alopecia areata in Sri Lankan adult patients. Ceylon Med J 2014;59:128-31.
21. Amirnia M, Sinafar S, Sinafar H, Nuri M. Assessment of Zinc and Copper Contents in Scalp Hair and Serum and Superoxide Dismutase, Glutathione Peroxidase and Malondialdehyde in Serum of Androgenetic Alopecia and Alopecia Areata Patients. Medical Journal of Tabriz University of Medical Sciences 2011;33:7-13.
22. Ostadrahimi A, Esfahani A, Jafarabadi MA, Ziaei JE, Movassaghpourakbari A, Farrin N. Effect of Beta Glucan on Quality of Life in Women with Breast Cancer Undergoing Chemotherapy: A Randomized Double-Blind Placebo-Controlled Clinical Trial. Advanced pharmaceutical bulletin 2014;4:471.
23. Moghimipour E, Salimi A, Leis F. Preparation and evaluation of tretinoin microemulsion based on pseudo-ternary phase diagram. Advanced pharmaceutical bulletin 2012;2:141.
24. Herizchi QH, Majidi J, Sheikh NM, Fadaii R. Results of complete blood cell count, Fasting blood suger, Rheumatoid factor, C-reactive protein, anti- nuclear abntibody and thyroid function tests in patients with Alopecia Areata. Medical Journal of Tabriz University of Medical Sciences 2011;33:82-5.
25. Fathi-Azarbayjani A, Ng KK, Chan YW, Chan SY. Lipid Vesicles for the Skin Delivery of Diclofenac: Cerosomes vs. Other Lipid Suspensions. Advanced pharmaceutical bulletin 2015;5:25.

How to cite this article: Amirnia M, Mahmoudi SS, Karkon-Shayan F, Alikhah H, Piri R, Naghavi-Behzad M, et al. Comparative study of intralesional steroid injection and cryotherapy in alopecia areata. Niger Med J 2015;56:249-52.

Source of Support: Nil, Conflict of Interest: None declared.